Novo Nordisk seeks to develop obesity prevention drugs
白云追月素
发表于 2023-12-5 20:51:22
329
0
0
On December 5th, Novo Nordisk is conducting experiments and research to understand the causes of obesity and seeking to develop drugs to prevent obesity.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- Novo Nordisk to invest 864 million Brazilian reals to renovate insulin factory in Brazil
- Novo Nordisk reaches settlement with Mylan Pharmaceuticals over patent dispute over weight loss drug Ozempic and Wegovy
- GlaxoSmithKline agrees to pay up to $2.2 billion to resolve approximately 80000 lawsuits related to the heartburn drug Zantac
- GlaxoSmithKline agrees to pay up to $2.2 billion to resolve approximately 80000 lawsuits related to the heartburn drug Zantac
- Novo Nordisk has participated in the CIIE for seven consecutive years, working together with various sectors to promote the concept of "healthy metabolism"
- Novo Nordisk warns of the risk of compound generic semaglutide, which has caused 10 deaths and 100 hospitalizations
- Lai Lai scares, Novo Nordisk saves the scene! The market prospects of weight loss drugs still make many players salivate
- Novo Nordisk: All regulatory delivery conditions for Novo Nordisk's $16.5 billion acquisition of Contante have been met
- Novo Nordisk invests 8.5 billion Danish kroner to build new production facility in Odense, Denmark
- Novo Nordisk's pre-market decline narrows to 20%
